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Cost analysis of chemotherapy 
in advanced non-small cell lung cancer
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Jarosław Mądrzak3, Rodryg Ramlau4, Helena Żukowska5, Tomasz Szczęsny2,
Marcin Gołecki5, Hanna Wolf6, Jacek Jassem3
In tr o d u c t io n . Financial constrains on health care delivery have forced decision-makers and resource providers in most co­
untries to identify interventions that combine clinical benefit with cost-effectiveness. Lung cancer is the leading cause o f can­
cer deaths in Poland, with about 20.000 new cases diagnosed annually and approx. 19.000 deaths. Non-small cell lung 
cancer (NSCLC) accounts for 80% o f all lung cancer cases. The cost o f drugs is not the only component o f the overall che­
motherapy-related expenditures. Pharmacoeconomic analysis allows to evaluate all costs and select the most cost-effective tre­
atment strategy.
A im  o f  s tu d y . To estimate the direct costs o f three different chemotherapy regimens for advanced NSCLC: cisplatin plus 
etoposide (PE), cisplatin plus vinorelbine (PN), and cisplatin plus gemcitabine (PG).
Material and Method. The analysis was conducted on 87patients treated between 1997 and 1999 in five institutions. The pay­
er's perspective was adapted and only medical costs were included.
R esu l t s .  The mean ‘‘cost per cycle ” (all expenditures used during management o f single patient) for PE, PN and PG regi­
mens were 2.530 PLN, 3.609 PLN, and 5.104 PLN, respectively. The cost o f anticancer drugs was the principal component, 
generating the highest expenses for PG regimen, whereas the cost o f hospitalization was the most important factor in genera­
ting expenses for PN and PE regimens.
C o n c l u s i o n s .  The analysis revealed the cost o f drugs and the in-patient administration o f chemotherapy to be the main so­
urces o f expenditure during chemotherapy for advanced NSCLC. The economic evaluation is feasible in Polish conditions and 
may provide essential information for health care providers and payers. It is mandatory to perform a prospective study with the 
use o f  cost-effectiveness analysis.
Analiza kosztów chemioterapii zaawansowanego niedrobnokomórkowego raka piuca
Wstęp.  Ograniczone zasoby finansowe zmuszają do szukania dowodów naukowych dla określenia skuteczności i opłacal­
ności poszczególnych metod leczenia. Rak płuca jest najczęstszą przyczyną zgonów na nowotwory w Polsce. Liczba nowych 
zachorowań wynosi około 20000 osób rocznie, a liczba zgonów -  prawie 19000. Około 80% wszystkich nowotworów płuca 
stanowi rak niedrobnokomórkowy (NDRP). Koszt leków nie jest jedyną składową ogólnych wydatków związanych z chemio­
terapią. Analizy farmakoekonomiczne, oceniając wszystkie koszty, pomagają w wyborze optymalnych metod leczenia w aspek­
cie medycznym i finansowym.
C el bada n ia .  Celem badania była ocena, z punktu widzenia płatnika, bezpośrednich kosztów chemioterapii w odniesieniu 
do trzech programów chemioterapii zaawansowanego NDRP: cispłatyny i etopozydu (PE), cisplatyny i winorelbiny (PN) oraz 
cisplatyny i gemcytabiny (PG).
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M eto dy .  Analizą objęto 8 7 chorych leczonych w 5 ośrodkach w latach 1997-1999.
Wyniki .  Głównym elementem wydatków w programie PG były cytostatyki, podczas gdy w programach PN i PE  -  koszty hos­
pitalizacji. Średni koszt cyklu (wszystkie wydatki związane z leczeniem u jednego chorego) przy użyciu schematów PE, PN, PG 
wynosiły odpowiednio 2530, 3609 i 5104 PLN.
W n io s k i .  Analiza wykazała, że koszt chemioterapii zaawansowanego NDRP jest związany głównie z kosztami leków 
i prowadzeniem chemioterapii w warunkach szpitalnych. Analiza farmakoekonomiczna jest możliwa do przeprowadzenia i m o­
że dostarczyć ważnych informacji zarówno dla świadczeniodawców, jak i płatników. Niezbędne jest przeprowadzenie prospek­
tywnego badania z użyciem analizy koszt-efektywność.
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Introduction
The total expenses for medical care in most countries 
constitute a considerable portion of the Gross National 
Product. At present, an easy and unlimited access to all ty­
pes of treatm ent is not possible in any health care sys­
tem in the world. At the same time, there is an over-con­
sumption of medical services by the societies in general. 
Increasing financial constrains on health care delivery in 
most countries force the decision-makers to identify inte­
rventions that combine clinical benefit and cost-effective­
ness. The choice of treatment in oncology is a difficult 
ethical issue. One of the reasons is a limited access to 
some therapeutic modalities due to economic constra­
ints. Pharmacoeconomics, with its array of methods, pro­
vides a possibility of assessing costs of procedures and 
their actual benefits.
Lung cancer is the most frequent malignancy in 
Poland, with more than 20.000 new cases diagnosed each 
year and approximately 19.000 deaths. Non-small cell 
lung cancer (NSCLC) accounts for 80% of all lung cancer 
patients {nearly 16.000 new cases annually) and its in ci- 
dence is constantly increasing [lj. About 75% of all pa­
tients with NSCLC in Poland present with either locally 
advanced or metastatic disease. These patients cannot 
be managed with radical surgery. Locally advanced pa­
tients are treated with either radiotherapy alone or radio­
therapy combined with chemotherapy, but the five-year 
survival rates are only in the range of 3-10%. Palliative ra­
diotherapy, chemotherapy or best supportive care (BSC), 
are possible therapeutic options for patients with stage IV 
metastatic disease. Over the years, the role of palliative 
chemotherapy in stage IV NSCLC was a m atter of di­
scussion. In the last decade growing evidence has sup­
ported the value of this method. The recent Cambridge 
metaanalysis of all randomized clinical trials has shown 
that cisplatin-based chemotherapy could increase one­
-year survival by 10% [2]. It was also shown that chemo­
therapy can relieve cancer-related symptoms in at least 
50% of patients [3], The American Society of Clinical 
Oncology (ASCO) has issued clinical guidelines for the 
treatm ent of unresectable NSCLC [4]. The ASCO gu­
idelines indicate systemic chemotherapy as a standard 
approach for advanced NSCLC. However, patients sho­
uld meet certain clinical criteria (e.g. good performance 
status, stable body weight and assessable disease).
The progress in the treatment of advanced NSCLC 
depends on the implementation of new drugs with hi­
gher activity. Several new agents (vinorelbine, gcmcitabi- 
ne, paclitaxel and docetaxel) have been demonstrated to 
be more effective and usually better tolerated than their 
older counterparts. Of particular value is the use of new 
agents in multi-drug regimens [5-7]. Unfortunately, these 
agents are considerably more expensive than older drugs 
[8]. Despite many clinical studies no chemotherapy regi­
men has been found to be superior to the others. The 
recent ECOG study of the four most commonly used 
chemotherapy regimens, including new agents in combi­
nation with platinum compounds, has showed similar ac­
tivity [9], Many studies have attempted to evaluate real 
costs of chemotherapy of advanced NSCLC. However, 
these studies were performed under different economic 
circumstances and do not necessarily correspond to clini­
cal practice and financial realities in Poland.
The aim of the present study was to estimate the di­
rect costs of three commonly used chemotherapy regi­
mens for advanced NSCLC: cisplatin and etoposide (PE), 
cisplatin and vinorelbine (PN), and cisplatin and gemcita- 
bine (PG) under Polish circumstances.
Methods
The analysis was conducted on patients treated between 1997 
and 1999 in five Polish institutions. We analysed the cases of 
patients who had received chemotherapy beyond the scope of cli­
nical trials (routine practice). Patients diagnosed with advan­
ced NSCLC who had received at least two cycles of chemothera­
py were eligible for analysis. Chemotherapy was administered 
either in the in-patient or out-patient setting, depending on the 
institutional preferences and available facilities. Patients who 
had received preoperativc chemotherapy and/or radical radio­
therapy were not analyzed. Eighty-seven patients with advanced 
(stage 11IB not amenable for radical radiotherapy or stage IV) 
NSCLC were included in the study. Of those, 35 patients rece­
ived cisplatin (DDP) and vinorelbine (VRB) -  PN regimen, 24 
patients DDP and gemcitabine (GCB) -  PG regimen and 28 
patients DDP and etopsidc (VP16) -  PE regimen. The details of 
the regimens were: PN -  DDP 80 mg/m2 on day 1 + VRB 25 
mg/m2 on days 1 and 8; PE -  DDP 30 mg/m2 on day 1, 2 and 3 + 
VP16 120 mg/m2 on days 1, 2 and 3; PG -  DDP 80 mg/m2 on 
day 2 +  GCB 1000 mg/m2 on days 1 and 8. All regimens were 
administered every 21 days; all agents given intravenously. The 
mean number of administered cycles was 2.6 for PN, 5.2 for PG 
and 3.8 for PE (Table I). The differences in the mean number of 
cycles reflected the duration of treatment. Patients receiving 
gemcitabine-containing chemotherapy achieved better disease
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control. Therefore, the duration of chemotherapy (in consequen­
ce, the number of cycles) was prolonged compared with other re­
gimens. The differences were considered in the final resources 
consumption analysis. All groups of patients were similar with re­
spect to age, gender and disease stage (Table I). All pretreatment 
routine diagnostic procedures were identical in each group of pa­
tients. Both laboratory and radiographic examinations were per­
formed according to the same schedule. The costs of certain 
additional tests (individually required) were included into the 
analysis. However, they were performed incidentally with no 
impact on the results. In the analysis, the payee's perspective 
was adopted and only medical costs were taken into considera­
tion. The medical costs calculated in the study represent real 
expenditures on the management of patients (hospital-spent 
days, out-patient visits, all diagnostic procedures, total medica­
tion including anticancer and supportive therapy). The above co­
sts were calculated as follows:
-  cost of hospitalization (all costs of hospitalization, including 
the cost o f medical personnel),
-  cost o f ambulatory care (including physical examination; dia­
gnostic tests considered as consumption only if directly related 
to clinical evaluation of chemotherapy e.g. biochemistry and 
radiographic tests),
-  cost of cytotoxic agents (cost of medication unit available on 
the market -  for VP16 the cost of Vepesid1M was calculated), 
cost of antiemetic drugs.
The total cost of treatment was calculated by multiplying 
the mean cost of one cycle by the mean number of cycles. The 
following costs were not included in the final assessment:
-  costs of drug preparation by nurse or pharmacist,
-  costs related to dose reductions or omissions,
-  costs of therapy necessary to treat side effects of chemothera­
py (e.g. neutropoenia, neurotoxicity, etc),
-  costs o f analgetic drugs.
Total consumption of resources was calculated by multi­
plying the number of units by price of the unit. The prices of 
biochemistry and radiographic tests were obtained from the 
respective laboratory departments, whereas the costs of medica­
tion -  from hospital pharmacies. Information on costs of ho­
spitalization and ambulatory care, as well as on the consumption 
of resources, was obtained from the respective hospital financial 
departm ents. AH costs were calculated in Polish currency
(PLN) using prices for the first 6 months of the year 2000. The 
costs were evaluated for each hospital and every medical inte­
rvention separately. The total cost for each patient was divided 
by the total number of chemotherapy cycles to obtain a mean 
“cost per cycle”. The total costs for the group of patients were di­
vided by the number of patients to obtain a mean “cost per pa­
tient”.
Results
A s s e s s m e n t  o f  e f f e c t i v e n e s s  
One-year survival rates for patients in respective groups 
were as follows: PE -  32% (95% Cl 19-45%), PN -  37% 
(95% Cl 24-40%) and PG -  42% (95% Cl 25-59%). No 
statistically significant difference was detected among the 
three groups of patients.
C o n s u m p t i o n  o f  r e s o u r c e s  
The mean “cost per cycle” (all expenditures used during 
management of single patient) for PE, PN and PG regi­
mens were 2.530 PLN, 3.609 PLN, and 5.104 PLN, re­
spectively. Calculated mean “cost per patient” (average 
expenditures for the management within each analyzed 
group) was 9.658 PLN for PE, 9.417 PLN for PN and 
26.449 PLN for PG. The detailed calculation of all costs is 
presented in table II. The cost of drugs was the principal 
param eter that generated highest expenditures in PG- 
-treated group, whereas the cost of hospitalization was 
the most important factor generating expenses for PN 
and PE regimens. Additionally, we performed an analysis 
of the direct costs in particular institutions. To make the­
se comparisons more relevant we have analyzed the costs 
in the different institutions for the same chemotherapy 
regimens. For example, in two institutions using the PE 
regimen the total direct costs of treatm ent per patient 
were 5.509 PLN and 12.275 PLN, respectively. The same
Table I. C linical characteristics
R egim en
D ata
cisp latin-etoposide cisplatin-vinorclbinc cisplatin-gcm citabine
N um ber o f p a tien ts  (m ales/fem ales) 28 (25/3) 35 (32/3) 24 (20/4)
M edian  age (range) 59.5 (39-73) 58.4 (43-72) 59.4 (44-74)
Stage IIIB /IV 17/11 20/15 14/10
M ean num ber o f cycles (range) 3.8 ( 2 - 6 ) 2.6 ( 2 - 6 ) 5.2 ( 2 - 7 )
O ne-year survival ± 9 5 % C I (% ) 32%  (19-45% ) 37%  (24-40% ) 42%  (25-59% )
Table II- Mean cost o f treatment (PLN per one patient)
cisplatin-etoposide cisplatin -vinorelbine cisplatin-gem citabine
C ost o f cisplatin 312.72 232.12 438.64
C ost o f o th e r  cytostatics 634.55 3374.04 18477.44
C ost o f supportive  m edications 844.16 313.73 446.40
C ost o f hospitalization  +  am bulatory  care
and d iagnostic  p rocedures 7867.35 6204.40 4911.46
C ost o f  one cycle 2530.% 3609.08 5104.51
Total cost o f trea tm en t 9658.77 9417.61 26449.75
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Table III. Total direct cost of treatment per patient according to centre (in PLN)
C en tre  1
PN
C entre  2 C en tre  1
PG
C entre  3 C entre  2
PP.
C en tre  4
Cytostatics 5770.4 3145.9 18491.0 19981.8 848.44 1032.92
Supportive drugs 214.4 335.7 709.2 262.3 693.92 974.37
H ospitalization 3162.0 4815.0 844.0 624.4 2146.15 9020.46
A m bulatory  costs 642.3 550.8 652.8 184.9 835.69 0.00
Diagnostics 845.0 868.1 1526.4 1375.2 985.17 1246.77 .
figures for PN were 10.634 PLN and 9.715 PLN (ta ­
ble III).
Discussion and conclusions
It is estimated that diagnosis and treatment of NSCLC ac­
counts for 20% of the total expenditure for the manage­
ment of all malignancies and approximately 2% of the 
global health care costs [10,11], The results of treatment 
of NSCLC are still far from satisfactory. Five-year survival 
from the date of diagnosis is likely in only 12-16% of all 
NSCLC patients [12]. The unsatisfactory results evoke 
discussion on the optimal therapeutic strategy for 
NSCLC, especially on the role of chemotherapy in ad­
vanced stages. Chemotherapy, despite its palliative cha­
racter, has been found to provide modest survival benefit 
and better quality of life in selected patients with advan­
ced NSCLC.
Cost of drugs is not the only component of the ove­
rall chemotherapy-related expenditure. Pharmacoecono- 
mic analysis enables the evaluation of all costs and may fa­
cilitate the selection of most optimal treatment based on 
medical and economic grounds. It compares costs of tre­
atment and clinical results of different therapeutic moda­
lities. An optimal method of pharmacoeconomic asses­
sment is the cost-effectiveness analysis (CEA). With the 
use of CEA it is possible to make a comparison of finan­
cial aspects for standard and newly introduced modalities 
in the context of their clinical value. CEA evaluates health 
outcomes and costs of medical interventions. Its purpose 
is to show the relative value of alternative intervention for 
health improvement. It can also help decision-makers to 
weight alternatives and decide which ones meet best the­
ir expectations. The results of CEA are usually expressed 
as a cost-effectiveness ratio (CER) which demonstrates 
the cost of achieving one unit of health benefit in different 
groups of patients treated with the use of various inte­
rventions. Examples of clinical benefit used in such analy­
ses include the increased response rate, prolonged survi­
val, reduced use of supportive therapy (i.e. antiemetics, 
analgesics) and palliative radiotherapy, and shortening 
the duration of hospital stay. These parameters are crucial 
for the economy of treatment. They are also essential for 
the optimal management of patients. For example, shor­
ter hospitalization (chemotherapy in an outpatient set­
ting) is associated with both, lower costs and better quali­
ty of life of patients [13]. Unfortunately, for the methodo­
logical reasons we were not able to perform CEA analysis 
due to retrospective character of our study.
Several pharmacoeconomic studies have been per­
formed with the aim to select the most cost-effective che­
motherapy regimens in advanced NSCLC [14-21], The 
results have shown that palliative chemotherapy may be 
cost-effective. However, those results cannot be generali­
zed, due to large differences in health-care costs and co­
untry-specific variations in financing systems. Thus, there 
is an urgent need to perform separate analysis taking in­
to account the local situation in Poland. Obviously, not all 
patients with advanced NSCLC are candidates for syste­
mic therapy. It is recommended for patients with good 
performance status, with no serious comorbidity, with ac­
ceptable laboratory parameters (haematology profile, li­
ver and renal function tests) and, preferably, with m e­
asurable or at least evaluable disease. For patients who 
m eet the above criteria chem otherapy is justified as 
a standard care, whereas BSC should be reserved for all 
other patients. Since the criteria are restrictive, the majo­
rity of patients with advanced disease should be offered 
BSC only. However, due to the increasing number of ad­
vanced NSCLC patients in Poland (approximately 8.000 
cases newly diagnosed each year), even the thoroughly 
selected candidates for chemotherapy create both medical 
and economical challenge.
To the best of our knowledge the present study is 
the first published analysis of direct costs related to che­
motherapy in advanced NSCLC in Poland. Patients in 
this study were treated in different institutions and che­
motherapy was administrated according to standard crite­
ria [22], The numbers of patients analyzed per each parti­
cipating institution were low, when compared with the 
total numbers expected. There were several reasons for 
the discrepancy. First, only patients receiving chemothe­
rapy beyond the scope of clinical trials were included. 
Each institution was involved in numerous clinical trials 
between 1997 and 1999. Second, the study methodology 
reduced the enrolment of patients -  only patients identi­
cally diagnosed, staged and monitored were considered. 
Third, for a significant number of patients we were unable 
to obtain complete data on the resources consumption 
retrospectively. Fourth, patients were supposed to receive 
at least 2 chemotherapy cycles and continue in case of 
objective clinical benefit. Keeping in mind the rate of ob­
jective responses in a range of 20-30% in advanced 
NSCLC it is obvious that the number of patients analyzed 
was lower than could be expected from a total number of 
patients treated. The present analysis was performed re­
trospectively and was focused on the economical issues of 
the routine practice. We decided to select chemotherapy
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Referencesregimens which were most commonly used in Poland du­
ring the analyzed period. W hat is important, we did not 
intend to identify the optimal regimen. Our aim was to 
perform a preliminary study in order to verify the feasibi­
lity of direct cost estimation in Polish conditions. Three 
DDP-based chemotherapy regimens were investigated: 
VP16-containing (PE), VRB-containing (PN) and GCB- 
-containing (PG). In our series all regimens were compa­
rable in terms of clinical efficacy.
The major limitation of this study is its retrospective 
character. Furthermore, this series included only patients 
who had received at least two chemotherapy cycles. Since 
chemotherapy in advanced NSLCL is usually continued 
until progression (but not exceeding six cycles), in our 
series patients were “positively” selected by excluding 
subjects with early progression. The mean number of cyc­
les with PE, PN and PG regimens were 3.8, 2.6, and 5.2, 
respectively, and this factor contributed considerably to 
the total costs of treatm ent. Some recent studies have 
suggested that in advanced NSCLC there is no benefit 
in terms of survival, in continuing chemotherapy for mo­
re than three cycles in patients with objective response 
[23]. Therefore it is likely that similar results might have 
been obtained with the equal number of cycles for each of 
the three regimens. Importantly, the indirect costs, such as 
loss of salary and employment absence, have not been 
taken into consideration. We noted substantial differences 
in the total cost of treatm ent between participating in­
stitutions. Chemotherapy was administered either in the 
day-care system or in the hospital. This had major influen­
ce on the total expenditure. The differences of accom­
modation expenditure were minute in relation to the total 
costs.
Our results definitely require confirmation in a pro­
spective study. Thus, our data must be considered as pre­
liminary. Despite its limitations, the present study provi­
des valuable information on the direct costs of chemothe­
rapy in advanced NSCLC. Moreover, it illustrates the 
ways of cost saving, i.e. ambulatory administration of che­
motherapy, meticulous use of concomitant medication, 
etc. As mentioned above, this study provides only prelimi­
nary estimation of the financial issues related to the treat­
ment of advanced NSCLC. The complete cost-effective - 
ness evaluation could only be accomplished in a prospec­
tive randomized study, which is planned in the nearest 
future.
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